[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-rhinitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-rhinitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,53,77,101,121,138,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100636658","efficacy-and-safety-of-high-concentration-35-kda-hyaluronan-gel-for-chronic-nasopharyngitis-100636658",false,"NCT07568548","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Chronic Nasopharyngitis","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Ultra-Rapid Relief of Skin Pruritus","HA35","Inclusion Criteria:\n\n* Age 18-80 years, male or female\n* Clinically diagnosed with chronic rhinitis and chronic pharyngitis for ≥3 months\n* Baseline nasopharyngeal discomfort NRS score ≥4 points\n* Baseline posterior pharyngeal discomfort NRS score ≥4 points\n* Voluntary participation and signed written informed consent\n* Ability to complete symptom assessment independently\n\nExclusion Criteria:\n\n* Acute upper respiratory tract infection within 2 weeks\n* Use of antihistamines, intranasal corticosteroids, decongestants, or other nasal medications within 2 weeks prior to screening\n* History of nasal\u002Fsinus surgery within 6 months\n* Known hypersensitivity to hyaluronan or any gel ingredients\n* Pregnant or lactating women\n* Severe systemic diseases or malignant tumors","ALL","18 Years","80 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of nasopharyngeal administration of 13.6% high-concentration 35 kDa hyaluronan (HA35) care gel in subjects with chronic rhinitis and chronic pharyngitis. Eligible participants will receive the study gel twice daily for 10 consecutive days. The primary objectives are to assess rapid changes in nasopharyngeal discomfort, posterior pharyngeal discomfort, and nasal obstruction within 30 minutes after the first administration. Secondary objectives include evaluation of overall symptom improvement at day 10, changes in subjective mental clarity, and safety and tolerability throughout the treatment period. This is a minimal-risk, non-pharmacological supportive care intervention.",[28,29,30,31,32],"Chronic Rhinitis","Chronic Pharyngitis","Nasopharyngitis","Posterior Pharyngeal Inflammation","Nasal Obstruction",[34,35,15,36,28,29,37,38,39,40],"Hyaluronan","35 kDa Hyaluronan","Nasopharyngeal Care","Nasal Congestion","Pharyngeal Discomfort","Non-pharmacological Intervention","Pilot Clinical Study","NOT_YET_RECRUITING","2026-05-05",{"date":44,"type":45},"2026-05-08","ACTUAL",{"date":47,"type":22},"2026-05-01",{"date":49,"type":22},"2026-07-01",{"name":51,"class":52},"Nakhia Impex LLC","INDUSTRY",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100562065","evaluation-of-pulsed-field-ablation-of-the-posterior-nasal-nerve-for-chronic-rhinitis-100562065","NCT06598319","Evaluation of Pulsed Field Ablation of the Posterior Nasal Nerve for Chronic Rhinitis","Inclusion Criteria:\n\n1. The subject is 18 to 85 years of age.\n2. The subject has had symptoms of chronic rhinitis for greater than 6 months with insufficient response to nasal steroids.\n3. The subject has an rTNSS total score of ≥ 6.\n4. The subject has had moderate to severe symptoms of rhinorrhea and\u002For nasal congestion (rTNSS rating of 2 or 3 for rhinorrhea and 1, 2, or 3 for congestion)\n5. The subject is able and willing to provide written informed consent and comply with the protocol requirements.\n\nExclusion Criteria:\n\n1. The subject has clinically significant anatomic obstructions on either side that limit access to the posterior nose, including severe septal deviation, nasal polyps, and sinonasal tumor\n2. The subject has a septal perforation\n3. The subject has had prior sinus or nasal surgery on either side that significantly alters the anatomy of the posterior nose.\n4. The subject had had previous surgery of the PNN for chronic rhinitis.\n5. The subject has had prior head or neck irradiation\n6. The subject has an active or chronic nasal or sinus infection\n7. The subject has active coagulation disorder, or the patient is receiving anticoagulants\n8. The subject has a history of dry eye or dry nose symptoms\n9. Patient has rhinitis medicamentosa\n10. The subject has ocular allergic symptoms\n11. The subject has a history of nose bleeds\n12. The subject has electrically sensitive implants (e.g. cochlear implants, pacemakers, defibrillators)\n13. The subject is pregnant or lactating\n14. The subject is participating in another clinical research study\n15. The subject has an allergy or intolerance to anesthetic agent\n16. Any physical condition that, in the Investigator's opinion, would prevent adequate study participation or pose an increased risk","85 Years",{"count":21,"type":22},[25],"Evaluation of safety, effectiveness and tolerability of the Aventix Medical Device used for the treatment of chronic rhinitis",[28],[65],"rhinitis, posterior nasal nerve","RECRUITING","2026-04-25",{"date":69,"type":45},"2026-04-30",{"date":71,"type":45},"2024-11-15",{"date":73,"type":22},"2026-12",{"name":75,"class":52},"Aventix Medical Inc.",3,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100592869","study-on-the-optimization-of-the-diagnostic-process-for-chronic-rhinitis-using-nasal-allergen-provocation-test-100592869","NCT06999044","Study on the Optimization of the Diagnostic Process for Chronic Rhinitis Using Nasal Allergen Provocation Test","Inclusion Criteria:\n\nAR patients:\n\n* Aged 18-75 years;\n* patients who visited the Department of Otorhinolaryngology,the First Affiliated Hospital of Nanjing Medical Uncversity and were willing to undergo nasal provocation test; 3.Ptients who are willing to provide specimens for free to promote the study of the diagnostic efficacy of nasal provocation.\n\nHealthy volunteers:\n\n* Aged 18-75 years;\n* Did not have any nasal symptoms and tested negative for allergens\n\nExclusion Criteria:\n\n* Acute rhinosinusitis or acute exacerbation of chronic rhinosinusitis; active phase or symptom exacerbation of allergic diseases (e.g., allergic rhinitis, asthma).\n* History of severe allergic reactions (e.g., anaphylaxis).\n* Severe chronic obstructive pulmonary disease (COPD) or severe cardiopulmonary diseases contraindicating epinephrine use.\n* Active phase of other severe systemic diseases (e.g., malignancies, autoimmune diseases).\n* Within 1 week post-vaccination.\n* Pregnancy, lactation, or preconception period.\n* Inability to comply with study procedures (particularly children under 5 years old).\n* Recent nasal surgery (within 2 months), nasal deformities (e.g., choanal atresia, severe nasal septum deviation\u002Fperforation), dry\u002Fatrophic rhinitis, severe nasal obstruction (e.g., hypertrophic rhinitis, rhinitis medicamentosa), or uncontrolled epistaxis.\n* Current use of anti-allergy medications, including:Intranasal agents: corticosteroids, antihistamines, decongestants, anticholinergics, sodium cromoglicate;Systemic agents: oral antihistamines, oral\u002Finjectable corticosteroids.",true,"75 Years",{"count":86,"type":22},100,"OBSERVATIONAL","Chronic rhinitis (CR) is one of the most prevalent global diseases, with studies estimating that up to 30% of the worldwide population is affected. In China, the prevalence of chronic rhinitis ranges from 10% to 40%, impacting over 300 million individuals. Although non-fatal, CR significantly disrupts daily work and academic performance, predisposes patients to respiratory comorbidities such as nasal polyps and asthma, and may induce systemic complications (e.g., secretory otitis media). Additionally, it detrimentally affects mental health, contributing to psychological disorders, substantial healthcare expenditures, and socioeconomic burdens.\n\nClinically, CR is broadly classified into allergic rhinitis (AR) and non-allergic rhinitis (NAR) based on skin prick test (SPT) and\u002For serum-specific IgE results. However, real-world clinical complexity arises as a subset of patients exhibit AR symptoms despite negative test results (local allergic rhinitis), while others with confirmed AR evade detection via conventional methods. This challenges the traditional dichotomous classification, highlighting its growing inadequacy. Given divergent therapeutic strategies for CR subtypes, ambiguous classification frequently leads to ineffective clinical outcomes, necessitating a gold-standard diagnostic framework for precise phenotyping.\n\nThe nasal allergen provocation test (NAPT), internationally recognized as the diagnostic gold standard for AR and local allergic rhinitis, directly applies allergens to nasal mucosa to elicit or exacerbate symptoms. Endorsed by global guidelines (e.g., ARIA, EPOS), NAPT has demonstrated safety through over a decade of clinical refinement. Despite its advantages, current protocols involve multi-dose allergen challenges at varying concentrations, rendering the procedure time-prohibitive and limiting clinical adoption. Developing a simplified, standardized provocation method is an urgent unmet need to expedite practical application.",[28],"2025-05-22",{"date":92,"type":45},"2025-05-31",{"date":94,"type":45},"2025-03-24",{"date":96,"type":22},"2028-12-01",{"name":98,"class":99},"The First Affiliated Hospital with Nanjing Medical University","OTHER",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100568549","diagnostic-efficacy-of-cda-nasal-provocation-test-in-patients-with-ir-100568549","NCT06682676","Diagnostic Efficacy of CDA Nasal Provocation Test in Patients With IR","To Study the Diagnostic Efficacy of Cold Dry Air (CDA) Nasal Provocation Test in Patients With Idiopathic Rhinitis (IR)","Inclusion Criteria:\n\n* IR patients: 1. Aged 18-65 years; 2. The presence of symptoms of rhinitis for more than 2 years, often triggered by non-specific stimuli, serum and nasal secretion allergen specific IgE test negative, nasal endoscopy examination ruled out severe anatomical disease and sinusitis with or without polyps, nasal secretion smear no eosinophils, allergic rhinitis, local allergic rhinitis, eosinophilia non-allergic rhinitis were excluded; 3. IR patients who visited the Department of Otorhinolaryngology, the First Affiliated Hospital of Nanjing Medical University and were willing to undergo CDA nasal provocation test; 4.Ptients who are willing to provide specimens for free to promote the study of the diagnostic efficacy of CDA nasal provocation test for IR.\n* Healthy volunteers: 1. Aged 18-65 years; 2. Did not have any nasal symptoms and tested negative for allergens.\n\nExclusion Criteria:\n\n* 1\\. Patients received glucocorticoids, immunomodulatory drugs, antihistamines, and other treatments that may affect the study results within the past 1 month. 2. Patients with unstable diseases (including severe asthma) and active immune system diseases; 3. Smoking; 4. Pregnant or lactating women; History of nasal surgery within 5.3 months; 6. Patients with any nasal conditions that may interfere with the efficacy or safety evaluation of CDA nasal provocation test; 7. Patients with low compliance and refusing to accept specimen and questionnaire collection.","65 Years",{"count":86,"type":22},[25],"Chronic rhinitis is a common chronic nasal mucosal inflammatory disease. Its clinical symptoms and severity are diverse, mainly including allergic rhinitis, local allergic rhinitis, non-allergic rhinitis with hypereosinophilia syndrome and idiopathic rhinitis. All kinds of rhinitis have clinical symptoms such as nasal congestion, runny nose, sneezing, and nasal itching, but the causes are different. At present, the diagnosis of idiopathic rhinitis (IR) is based on detailed medical history and negative allergen test results, which is a diagnosis of exclusion. According to the position paper of the European Academy of Allergy and Clinical Immunology (EAACI), nasal hyperresponsiveness is an abnormal reaction of the nasal mucosa to stimuli that most people can tolerate. One of the distinguishing features of non-allergic rhinitis. cold dry air (CDA) nasal provocation test has been proved to be a good, safe and tolerable test for nasal hyperresponsiveness, with superior sensitivity and specificity. At present, there is still a lack of clear diagnostic criteria for IR. Therefore, optimizing CDA nasal provocation test, determining the diagnostic efficacy of CDA nasal provocation test with different parameters for IR, and initially constructing an IR diagnostic model can provide more comprehensive guidance for clinical diagnosis and treatment, which has important clinical significance.",[28],"2024-11-08",{"date":115,"type":45},"2024-11-12",{"date":117,"type":22},"2024-11-07",{"date":119,"type":22},"2032-12-31",{"name":98,"class":99},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":128,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100568216","characteristic-transcriptomic-proteomic-and-metabolomic-molecular-studies-of-nasal-secretions-from-chronic-rhinitis-100568216","NCT06678334","Characteristic Transcriptomic, Proteomic and Metabolomic Molecular Studies of Nasal Secretions From Chronic Rhinitis","Characterization of Transcriptome, Proteome and Metabolome Molecules in Nasal Secretions of Different Subtypes of Chronic Rhinitis","Inclusion Criteria:\n\n1. Age 18-65 years old;\n2. Patients with chronic rhinitis in the Department of Otorhinolaryngology, the First Affiliated Hospital of Nanjing Medical University;\n3. Patients who are willing to provide specimens for free to promote the diagnosis of chronic rhinitis.\n\nExclusion Criteria:\n\n1. Patients received glucocorticoids, immunomodulatory drugs, antihistamines, and other treatments that may affect the study results within the past 1 month.\n2. Patients with unstable diseases (including severe asthma) and active immune system diseases;\n3. Smoking;\n4. Pregnant or lactating women; History of nasal surgery within 5.3 months;\n\n6\\. Patients with low compliance and refusing to accept specimen and questionnaire collection",{"count":129,"type":22},1000,"Chronic rhinitis is a common chronic nasal mucosal inflammatory disease. Its clinical symptoms and severity are diverse, mainly including allergic rhinitis, local allergic rhinitis, non-allergic rhinitis with hypereosinophilia syndrome and idiopathic rhinitis. All kinds of rhinitis have clinical symptoms such as nasal congestion, runny nose, sneezing, and nasal itching, but the causes are different. At present, the complicated diagnostic methods of different subtypes of chronic rhinitis are an important factor restricting the improvement of clinical diagnosis and treatment. Based on the found key markers of each subtype of chronic rhinitis, the establishment of a non-invasive classification diagnostic method of chronic rhinitis with nasal secretion as the core is of great practical significance for optimizing the existing clinical diagnosis system and improving the efficiency of clinical diagnosis",[28],"2024-11-06",{"date":117,"type":45},{"date":132,"type":22},{"date":136,"type":22},"2032-12-01",{"name":98,"class":99},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":100},"100544560","the-epidemiological-and-intrinsic-characteristics-of-chronic-rhinitis-100544560","NCT06370468","The Epidemiological and Intrinsic Characteristics of Chronic Rhinitis","To Elucidate the Epidemiological, Clinical, and Intrinsic Characteristics of Chronic Rhinitis","Inclusion Criteria:\n\nChinese aged between 18 and 70 years old who have resided at the survey site for more than 6 months within the 12 months preceding the survey.\n\nExclusion Criteria:\n\nExclusion criteria for questionnaire recipients: ① residents in specialized facilities (e.g., workshops, military barracks, student dormitories, nursing homes); individuals with mental or cognitive disorders (including dementia, aphasia, deafness); Exclusion criteria for nasal examination participants: ① individuals who have undergone sinus or nasal surgery, or diagnosed with sinusitis, nasal polyps, or nasal\u002Fnasopharyngeal tumors in the past year; ② patients with cystic fibrosis or primary ciliary dyskinesia; ③ residents in specialized facilities (e.g., workshops, military barracks, student dormitories, nursing homes); individuals with mental or cognitive disorders (including dementia, aphasia, deafness); (5) individuals currently under treatment for newly diagnosed tumors; ⑥ volunteers deemed unsuitable for the study by the research team.","70 Years",{"count":147,"type":22},150000,"Chronic rhinitis affects 10-40% of China's population, or over 300 million people, and can lead to respiratory and psychological issues. Despite treatment progress, 30% of patients have poor outcomes, likely due to the disease's complexity and a lack of new treatment targets. The incidence is rising, but there's a lack of nationwide studies on its variations. This study addresses this through a multicentric survey to create a national database on chronic rhinitis, including epidemiological, clinical, and biological data. The goal is to understand chronic rhinitis's causes and risks, improve treatments, and develop preventive strategies. The study will survey 30,000 patients across China, using questionnaires and nasal exams, and preserve biological samples in a biobank for detailed analysis. This will lay the groundwork for understanding the disease's mechanisms, developing new diagnostics, and tailoring prevention and treatment approaches for different forms of chronic rhinitis.",[28],"2024-06-05",{"date":152,"type":45},"2024-06-10",{"date":154,"type":45},"2024-04-27",{"date":156,"type":22},"2027-08-01",{"name":158,"class":99},"Zheng Liu ENT",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":100},"100487402","phase-4-efficacy-of-azelastine-and-mometasone-irrigation-in-comparison-to-nasal-sprays-in-patients-with-chronic-rhinitis-100487402","NCT05626621","Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis","Inclusion Criteria:\n\n* Adults 18 years and older seeking treatment for chronic rhinitis and willing to undergo six months of topical therapy.\n* Diagnosis of Chronic Rhinitis.\n\nExclusion Criteria:\n\n* The patient has diagnosis(es) other than chronic rhinitis that can account for his\u002Fher symptoms (septal deviation, nasal valve collapse, chronic sinusitis).\n* Use of oral antihistamines or oral steroids, unless patient undergoes a 4 week washout period.\n* Smokers (tobacco, marijuana, vaping, etc.).\n* Known or suspected pregnancy, or lactation.\n* Other medical conditions that the investigator believed would confound the study.\n* Allergy to study drugs.",{"count":166,"type":22},81,[168],"PHASE4","The goal of this clinical trial is to determine the best combination of drugs and drug delivery routes to treat surgically naive chronic rhinitis patients. The main question it aims to answer is:\n\nDo high volume, high pressure delivery mechanisms in nasal irrigation improve the efficacy of azelastine combined with nasal steroid mometasone as compared to the standard low pressure, low volume delivery mechanisms in nasal sprays?\n\nSubjects will complete six months of one of three medication regimens:\n\n1. Saline irrigation followed by azelastine spray and mometasone spray\n2. Mometasone saline irrigation\n3. Azelastine saline irrigation combined with mometasone saline irrigation.",[28],[172,173,174,175,176,177],"mometasone","azelastine","irrigation","topical therapy","nasal spray","chronic rhinitis","2023-07-25",{"date":180,"type":45},"2023-07-28",{"date":182,"type":45},"2022-11-23",{"date":184,"type":22},"2026-08",{"name":186,"class":99},"Endeavor Health"]